Ford Motor Co. on Tuesday reported a $2.1 billion first-quarter profit, said it will deliver a “solid profit” for the year and boosted its second-quarter North America production by another 30,000 ... Read More
Spartech Corp. said Monday it picked Maryland Heights as the location of its new technology and innovation center. The new Technology and Innovation Center, a 90,000-square-foot facility at 11650 Lakeside Crossing ... Read More
Saint Louis University today announced a $5 million grant from the Alberici Foundation to establish the new Center for Sustainability — a first for the nation’s 28 Jesuit colleges and universities. ... Read More
Fori Automation Inc. could see revenue hit the $100 million mark this year as efforts to diversify into the aerospace and defense industries continue to gain traction. The Shelby Township-based designer ... Read More
President Barack Obama will visit POET Biorefining – Macon, Mo. on Wednesday, April 28, as part of his “White House to Main Street Tour” through Missouri, Iowa and Illinois, the White ... Read More
Each year about a million people visit the Worlds of Fun and Oceans of Fun theme parks in Kansas City, Missouri, most of them unaware of an even stranger attraction lying ... Read More
Stifel Financial Corp. said Monday it plans to buy San Francisco investment bank Thomas Weisel Partners for more than $300 million in stock. The deal will create a middle-market investment bank ... Read More
Sensient Technologies Corp. of Milwaukee said it plans to invest $16 million at its Color Group headquarters in St. Louis. Sensient will build an additional 25,000-square-foot facility dedicated to natural colors ... Read More
CenturyTel Inc. agreed Thursday to buy Qwest Comunications International Inc. in an all-stock deal valuing Qwest at about $10.6 billion—one of the biggest U.S. telecommunications deals in years. The merger will ... Read More
The US Food and Drug Administration (FDA) has approved Zortress oral tablets for the prevention of rejection of kidney transplants in adult patients at low-to-moderate immunologic risk. Zortress is to be ... Read More